Arcus Biosciences Completes Patient Enrollment in Phase III Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers

Arcus Biosciences, Inc. announced the completion of patient enrollment for STAR-221, a Phase III study in collaboration with Gilead Sciences, evaluating the combination of the Fc-silent anti-TIGIT antibody domvanalimab plus the anti-PD-1 monoclonal antibody zimberelimab and chemotherapy in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.